概括
这项研究调查了莱斯塔尔提尼如何通过上调DR5.5来增强质瘤中TRAIL诱导的亡. 然而,由于对图像重复的担忧,该文章被撤回,使其结论受到损害.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞死亡研究 细胞死亡研究
背景情况:
- 质母细胞瘤 (GBM) 是一种具有有限治疗选择的侵袭性脑瘤.
- 与瘤亡因子相关的诱导亡的配体 (TRAIL) 通过诱导亡显示出癌症治疗的潜力.
- 制定提高GBM中TRAIL敏感性的策略对于有效治疗至关重要.
研究的目的:
- 调查莱斯塔乌提尼布通过哪种机制在质瘤细胞中增强 TRAIL 诱导的亡.
- 探索C/EBP同源蛋白 (CHOP) 和死亡受体5 (DR5) 在这个过程中的作用.
主要方法:
- 用莱斯塔乌尔提尼布和TRAIL治疗瘤细胞系.
- 使用流式细胞计和西式斑点测试来评估亡水平.
- 分析了CHOP和DR5的表达.
主要成果:
- 莱斯塔乌尔提尼布治疗显著增强了质瘤细胞中TRAIL诱导的亡.
- 这种增强与DR5.5的表达增加有关.
- 确定CHOP是诱导DR5.5的关键调解者.
结论:
- 莱斯塔乌提尼布可以使质瘤细胞对TRAIL诱导的亡敏感.
- 该机制涉及通过CHOP依赖的途径诱导DR5.
- 这些发现表明了质母细胞瘤的潜在治疗策略.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.4K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
